Blog Archives

PRESS RELEASE: Great Lakes NeuroTechnologies Continues Intellectual Property Growth As New Patent Claims Focus On Parkinson’s Device Accuracy And Sensitivity

VIEW PRESS RELEASE 05 MAR 2014: Valley View, OH – Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.


Next webinar: Teaching and Applying EMG to Human Movement

by Marcelo Aller, CSCS, Global BioRadio Sales Manager GLNT’s 2014 webinar series is designed to educate participants about the BioRadio wireless physiological monitoring system and to generate discussion about potential applications. We typically discuss a broad range of applications but our next webinar should be of particular interest to educators.

Read more ›


Objective Motion Sensor Assessment Highly Correlated with Scores of Global Levodopa-Induced Dyskinesia in Parkinson’s Disease

T. Mera, M. Burack, J. Giuffrida J Parkinsons Dis. 2013 Jan 1;3(3):399-407.


Tradeshow Event: Partnership in Clinical Trials

The Mirage Hotel Las Vegas, NV March 31 – April 2 2014 Conference home page We will be exhibiting at booth #1305 . We will be demonstrating out Kinesia HomeView and ProView systems. From the 2013 event: This year’s event brings together upwards of 1300 clinical decision makers for four

Read more ›


PRESS RELEASE: GLNT Awarded Patent For Sensor Based Continuous Parkinson’s Assessment During Daily Activities

VIEW PRESS RELEASE [PDF] 03 DEC 2013: Valley View, OH – Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of continuous monitoring of motor symptoms associated with movement disorders such as Parkinson’s disease. The

Read more ›


PRESS RELEASE: Great Lakes NeuroTechnologies Secures $1.7 Million to Develop Continuous Dyskinesia Monitoring Technology for Parkinson’s Disease

VIEW PRESS RELEASE [PDF]  05 Mar 2013: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease. The study is being funded by a $1,743,051 Phase II Small

Read more ›


Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology

T. Mera, M. Burack, J. Giuffrida Conf Proc IEEE Eng Med Biol Soc. 2012.


PRESS RELEASE: GLNT Begins Clinical Study to Demonstrate High Sensitivity Motor Symptom Detection in Parkinson’s Disease

VIEW PRESS RELEASE [PDF] March 23, 2012: Valley View, OH – Great Lakes NeuroTechnologies announced today that they have begun a clinical study to assess the sensitivity of their Kinesia system to detect subtle motor function changes in patients with Parkinson’s disease (PD). The study, funded by the National Institutes

Read more ›


PRESS RELEASE: GLNT Awarded Patent for Technology to Assess Parkinson’s Disease

VIEW PRESS RELEASE [PDF] 8MAR2012: Valley View, OH – Great Lakes NeuroTechnologies announced today that they have received allowance of claims from the U.S. Patent Office for an application covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders. The claims cover

Read more ›


Automated Parkinson’s Disease Gait and Balance Assessment for Optimization of Deep Brain Stimulation

T. Mera, D. Filipkowski, Riley R, Walter B, Gunzler S, J. Giuffrida International Congress of Parkinson’s Disease and Movement Disorders, Toronto, CA 2011